Chemoradiation with novel agents for rectal cancer

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Colorectal cancer treatment primarily relies on surgery.
• The role of radiation therapy in colon cancer is not well-defined, but it is extensively studied for locally advanced rectal cancer.
• Postoperative chemoradiotherapy improves local control and disease-free survival but not overall survival compared to surgery alone.

Purpose of the Study:

• To review the use of novel anticancer agents in combination with radiation therapy for treating locally advanced rectal cancer.
• To discuss the evolving treatment strategies for rectal cancer.

Main Methods:

• Review of clinical trials and studies on radiotherapy and chemoradiotherapy for rectal cancer.
• Analysis of preoperative versus postoperative combined-modality approaches.
• Investigation of novel systemic agents used with radiation therapy.

Main Results:

• Preoperative radiotherapy has demonstrated improved local control and survival advantages.
• Randomized studies comparing preoperative and postoperative chemoradiotherapy have faced challenges in the US.
• Preoperative treatment offers benefits like better patient tolerance, tumor downstaging, and reduced complications.

Conclusions:

• Preoperative chemoradiotherapy is a promising approach for locally advanced rectal cancer.
• 5-fluorouracil remains a standard chemotherapy agent with radiation, but novel agents are being explored.
• Further research into novel agents combined with radiation therapy is crucial for improving rectal cancer treatment outcomes.